New hope for rare bleeding disorder: sutacimig trial launches
NCT ID NCT07347249
First seen Jan 21, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study is testing a new drug called sutacimig in 18 adults with congenital factor VII deficiency, a rare condition that causes severe bleeding. The goal is to see if a single dose of the drug is safe and helps control bleeding. Participants will be monitored for side effects and how the drug works in their body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL FACTOR VII DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal London Hospital
RECRUITINGLondon, E1 2ES, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.